Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lifecore Biomedical, Inc. \De\ (LFCR) FCF Margin (2016 - 2025)

Historic FCF Margin for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to 8.92%.

  • Lifecore Biomedical, Inc. \De\'s FCF Margin fell 69300.0% to 8.92% in Q2 2025 from the same period last year, while for May 2025 it was 10.57%, marking a year-over-year increase of 35700.0%. This contributed to the annual value of 10.57% for FY2025, which is 35700.0% up from last year.
  • Per Lifecore Biomedical, Inc. \De\'s latest filing, its FCF Margin stood at 8.92% for Q2 2025, which was down 69300.0% from 12.11% recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s FCF Margin's 5-year high stood at 15.84% during Q2 2024, with a 5-year trough of 70.94% in Q1 2023.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s median FCF Margin value was 27.35% (recorded in 2024), while the average stood at 28.07%.
  • As far as peak fluctuations go, Lifecore Biomedical, Inc. \De\'s FCF Margin tumbled by -863900bps in 2021, and later surged by 491400bps in 2024.
  • Quarter analysis of 5 years shows Lifecore Biomedical, Inc. \De\'s FCF Margin stood at 39.98% in 2021, then rose by 29bps to 28.36% in 2022, then skyrocketed by 65bps to 9.86% in 2023, then crashed by -167bps to 26.35% in 2024, then skyrocketed by 134bps to 8.92% in 2025.
  • Its FCF Margin was 8.92% in Q2 2025, compared to 12.11% in Q1 2025 and 26.35% in Q4 2024.